Publications by authors named "R M Sharkey"
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of motor neurons in the brain and spinal cord. Accumulation of misfolded proteins is central to the pathogenesis of ALS and the glymphatic system is emerging as a potential therapeutic target to reduce proteinopathy. Using diffusion tensor imaging analysis along the perivascular spaces (DTI-ALPS) to assess glymphatic function, we performed a longitudinal analysis of glymphatic function in ALS and compared it to a disorder in the motor neuron disease spectrum, primary lateral sclerosis (PLS).
View Article and Find Full Text PDFArticle Synopsis
- Formal thought disorder (FTD) is a key symptom of schizophrenia, but its exact neurobiological causes and correlation with brain volume loss are still unclear, which this study seeks to address using a large cohort of patients and controls.
- The research focuses on differentiating between positive, negative, and total formal thought disorder while investigating brain structural changes and their cellular bases using virtual histology tools.
- Findings reveal distinct neural networks for positive and negative FTD, with negative FTD showing preserved orbitofrontal thickness and both FTD types linked to unique cellular fingerprint patterns, advancing our understanding of the disorder.
Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2-directed antibody conjugated with the topoisomerase I inhibitory drug, SN-38, via a proprietary hydrolysable linker. SG has received United States Food and Drug Administration (FDA) approval to treat metastatic triple-negative breast cancer (TNBC), unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, and accelerated approval for metastatic urothelial cancer. We investigated the utility of combining SG with platinum-based chemotherapeutics in TNBC, urinary bladder carcinoma (UBC), and small-cell lung carcinoma (SCLC).
View Article and Find Full Text PDFPrevious immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry.
Int J Infect Dis
February 2024
Objectives: To date, studies have not provided definitive answers regarding whether previous immune checkpoint inhibitor (ICI) treatment alters outcomes for cancer patients with COVID-19.
Methods: The OnCovid registry (NCT04393974) was searched from February 27, 2020, to January 31, 2022, for patients who received systemic anti-cancer therapy in the 4 weeks before laboratory-confirmed COVID-19 diagnosis. Propensity-score matching using country, vaccination status, primary tumor type, sex, age, comorbidity burden, tumor stage, and remission status investigated differences in predefined clinical outcomes comparing those who had or had not received ICIs.
Article Synopsis
- A study investigates the connection between formal thought disorder (FTD) symptoms in schizophrenia and brain volume deficiencies, using data from 752 individuals with schizophrenia and 1256 controls.
- The research identifies separate neural networks associated with positive and negative FTD, revealing differences in brain structures affected by each type of symptom.
- Findings show that negative FTD is linked to specific neuronal and astrocyte cell types, while positive FTD is associated with microglial cells, enhancing understanding of the biological mechanisms behind these symptoms.